TY - JOUR
T1 - The Effects of Direct Oral Anticoagulants, Warfarin, Aspirin and Thienopyridine on the Performance of Immunochemical, Faecal, Occult Blood Tests
AU - Niikura, Ryota
AU - Yamada, Atsuo
AU - Fujishiro, Mitsuhiro
AU - Tanaka, Kiyohito
AU - Matsuda, Koji
AU - Saito, Yutaka
AU - Ohtsuka, Kazuo
AU - Oda, Ichiro
AU - Katada, Chikatoshi
AU - Kato, Masayuki
AU - Kida, Mitsuhiro
AU - Kobayashi, Kiyonori
AU - Hoteya, Shu
AU - Horimatsu, Takahiro
AU - Kodashima, Shinya
AU - Matsuda, Takahisa
AU - Muto, Manabu
AU - Yamamoto, Hironori
AU - Ryozawa, Shomei
AU - Iwakiri, Ryuichi
AU - Kutsumi, Hiromu
AU - Miyata, Hiroaki
AU - Kato, Mototsugu
AU - Haruma, Ken
AU - Fujimoto, Kazuma
AU - Uemura, Naomi
AU - Kaminishi, Michio
AU - Shinozaki, Tomohiro
AU - Tajiri, Hisao
AU - Koike, Kazuhiko
N1 - Publisher Copyright:
© 2018 S. Karger AG, Basel.
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Aim: To clarify whether antithrombotic drugs affect diagnosis using the immunochemical faecal occult blood test -(iFOBT) of colorectal neoplasia. Methods: Using the Japan Endoscopy Database from 8 centres between 2015 and 2017, we analyzed data about patients who were iFOBT positive and had received direct oral anticoagulants (DOAC), warfarin, aspirin or thienopyridine. One-to-one matching-analogue propensity score weighted analyses were performed to compare the positive predictive value (PPV) of all neoplasms, invasive and non-invasive colorectal cancers and adenomas between drug users and non-users. All neoplasms included invasive and non-invasive colorectal cancer, and adenomas. Results: We analyzed 197 DOAC users and 196 non-users, 153 warfarin users and 153 non-users, 408 aspirin users and 415 non-users, and 97 thienopyridine users and 97 non-users. No significant differences were observed in the PPV for all neoplasms (56.67 vs. 50.43%), invasive cancer (4.32 vs. 3.53%), non-invasive cancer (15.58 vs. 15.56%) or adenoma (53.13 vs. 48.09%) between the DOAC user and non-user groups. No significant differences were observed in the PPV for all neoplasia, invasive and non-invasive cancer, or adenoma between warfarin, aspirin and thienopyridine use and non-users. Conclusions: DOAC, warfarin, aspirin and thienopyridine use did not decrease the PPVs of the iFOBT used to evaluate all colorectal neoplasia.
AB - Aim: To clarify whether antithrombotic drugs affect diagnosis using the immunochemical faecal occult blood test -(iFOBT) of colorectal neoplasia. Methods: Using the Japan Endoscopy Database from 8 centres between 2015 and 2017, we analyzed data about patients who were iFOBT positive and had received direct oral anticoagulants (DOAC), warfarin, aspirin or thienopyridine. One-to-one matching-analogue propensity score weighted analyses were performed to compare the positive predictive value (PPV) of all neoplasms, invasive and non-invasive colorectal cancers and adenomas between drug users and non-users. All neoplasms included invasive and non-invasive colorectal cancer, and adenomas. Results: We analyzed 197 DOAC users and 196 non-users, 153 warfarin users and 153 non-users, 408 aspirin users and 415 non-users, and 97 thienopyridine users and 97 non-users. No significant differences were observed in the PPV for all neoplasms (56.67 vs. 50.43%), invasive cancer (4.32 vs. 3.53%), non-invasive cancer (15.58 vs. 15.56%) or adenoma (53.13 vs. 48.09%) between the DOAC user and non-user groups. No significant differences were observed in the PPV for all neoplasia, invasive and non-invasive cancer, or adenoma between warfarin, aspirin and thienopyridine use and non-users. Conclusions: DOAC, warfarin, aspirin and thienopyridine use did not decrease the PPVs of the iFOBT used to evaluate all colorectal neoplasia.
KW - Colorectal neoplasia
KW - Direct oral anticoagulant
KW - Immunochemical faecal occult blood test
UR - http://www.scopus.com/inward/record.url?scp=85056378285&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056378285&partnerID=8YFLogxK
U2 - 10.1159/000494251
DO - 10.1159/000494251
M3 - Article
C2 - 30408803
AN - SCOPUS:85056378285
SN - 0012-2823
VL - 100
SP - 117
EP - 126
JO - Digestion
JF - Digestion
IS - 2
ER -